ASCO19: entrectinib displays promising results for rare tumor types in pediatric patients

Written by Mike Gregg, Future Science Group

A Phase I/IB study on entrectinib in pediatric populations has produced promising results in the treatment of rare central nervous system (CNS) tumors, neuroblastoma, or other solid tumors, which have fusions or mutations in the NTRK1/2/3, ROS1, or ALK genes. The study’s findings will be presented at the upcoming ASCO Annual Meeting (31 May – 4 June 2019, IL, USA). The study comes at an important time as very few studies have been conducted on targeted medicines for paediatric populations. In total, 29 patients were selected for the STARTRK-NG clinical trial with ages between 4.9 months – 20 years old...

To view this content, please register now for access

It's completely free